0.12
-0.006(-4.78%)
Currency In USD
| Previous Close | 0.13 |
| Open | 0.12 |
| Day High | 0.14 |
| Day Low | 0.1 |
| 52-Week High | 14.75 |
| 52-Week Low | 0.1 |
| Volume | 6.97M |
| Average Volume | 3.3M |
| Market Cap | 1.32M |
| PE | -0.01 |
| EPS | -22.01 |
| Moving Average 50 Days | 0.33 |
| Moving Average 200 Days | 3.21 |
| Change | -0.01 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of February 05, 2025 at a share price of $0.12. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0.01 as of February 05, 2025 at a share price of $0.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline
GlobeNewswire Inc.
Jan 15, 2025 1:00 PM GMT
The Company’s oncology aPKCi inhibitor is a novel, first in class drug candidateWARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advanc
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseas
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline
GlobeNewswire Inc.
Jan 08, 2025 1:00 PM GMT
All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder ValueWARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: